Dextromethorphan-Bupropion Moves Into Smoking Cessation While Its Case Against SSRIs Remains...

Thu, Sep 10

Perspectives

Axsome has dosed the first patient in a Phase 3 trial testing its depression drug, dextromethorphan-bupropion (Auvelity), as a stop-smoking treatment. It would be a third approved use, alongside depression and Alzheimer's-related agitation: https://t.co/5QovVICjHY

281

Axsome Therapeutics has begun a Phase 3 trial testing its depression drug, a combination of dextromethorphan and bupropion, as a smoking cessation aid. Th…

Discover